Zymeworks Inc. (NASDAQ:ZYME – Get Free Report) insider Paul Moore sold 39,741 shares of the company’s stock in a transaction that occurred on Friday, November 13th. The stock was sold at an average price of $26.07, for a total value of $1,036,047.87. Following the transaction, the insider owned 33,756 shares of the company’s stock, valued at approximately $880,018.92. This trade represents a 54.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Zymeworks Stock Performance
Shares of NASDAQ ZYME opened at $26.04 on Thursday. The business has a fifty day moving average of $27.20 and a two-hundred day moving average of $25.53. Zymeworks Inc. has a 52-week low of $21.52 and a 52-week high of $31.97. The stock has a market cap of $1.80 billion, a PE ratio of 50.08 and a beta of 1.32.
Zymeworks (NASDAQ:ZYME – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $2.27 by $0.01. The company had revenue of $512.92 million during the quarter, compared to analysts’ expectations of $227.40 million. Zymeworks had a net margin of 16.10% and a return on equity of 22.23%. The business’s quarterly revenue was up 828.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.26) earnings per share. Analysts predict that Zymeworks Inc. will post 1.31 earnings per share for the current year.
Analyst Upgrades and Downgrades
ZYME has been the subject of a number of research analyst reports. Jefferies Financial Group restated a “buy” rating and set a $52.00 price objective on shares of Zymeworks in a report on Friday, October 23rd. Weiss Ratings reissued a “sell (d-)” rating on shares of Zymeworks in a report on Thursday, October 15th. HC Wainwright upped their target price on shares of Zymeworks from $55.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday, November 10th. Truist Financial increased their price target on Zymeworks from $35.00 to $36.00 and gave the company a “buy” rating in a report on Tuesday, November 10th. Finally, B. Riley Financial reaffirmed a “buy” rating and set a $44.00 target price (up from $40.00) on shares of Zymeworks in a research report on Monday, August 10th. Twelve analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Zymeworks currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.
Get Our Latest Stock Analysis on ZYME
Institutional Investors Weigh In On Zymeworks
Several large investors have recently modified their holdings of ZYME. Nykredit A S acquired a new position in Zymeworks during the second quarter worth $25,000. Sterling Capital Management LLC increased its holdings in shares of Zymeworks by 813.3% during the third quarter. Sterling Capital Management LLC now owns 1,507 shares of the company’s stock valued at $40,000 after purchasing an additional 1,342 shares during the period. State of Wyoming acquired a new stake in Zymeworks in the 2nd quarter valued at about $73,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Zymeworks in the 3rd quarter valued at approximately $96,000. Finally, State of Alaska Department of Revenue acquired a new stake in shares of Zymeworks during the 3rd quarter valued at about $102,000. 92.89% of the stock is owned by institutional investors and hedge funds.
Zymeworks Company Profile
Zymeworks Inc. is a biotechnology company headquartered in Vancouver, Canada, that develops engineered medicines, with a focus on treatments for cancer and other serious diseases. Its antibody-engineering technologies are designed to create therapies that can engage multiple biological targets or modify immune responses. The company’s lead program is zanidatamab, a HER2-targeted bispecific antibody. In the United States, it is marketed by partner Jazz Pharmaceuticals as Ziihera for certain adults with previously treated, unresectable or metastatic biliary tract cancer.
Further Reading
- Five stocks we like better than Zymeworks
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Zymeworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zymeworks and related companies with MarketBeat.com's FREE daily email newsletter.
